Dynamics and specificities of T cells in cancer immunotherapy
G Oliveira, CJ Wu - Nature Reviews Cancer, 2023 - nature.com
Recent advances in cancer immunotherapy—ranging from immune-checkpoint blockade
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
DR Wang, XL Wu, YL Sun - Signal transduction and targeted therapy, 2022 - nature.com
Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …
malignant cells but also an altered immune response. The inhibition and reprogramming of …
[PDF][PDF] Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of IκBα
D Guo, Y Tong, X Jiang, Y Meng, H Jiang, L Du, Q Wu… - Cell metabolism, 2022 - cell.com
High expression of PD-L1 in tumor cells contributes to tumor immune evasion. However,
whether PD-L1 expression in tumor cells is regulated by the availability of nutrients is …
whether PD-L1 expression in tumor cells is regulated by the availability of nutrients is …
Kinase drug discovery 20 years after imatinib: progress and future directions
Protein kinases regulate nearly all aspects of cell life, and alterations in their expression, or
mutations in their genes, cause cancer and other diseases. Here, we review the remarkable …
mutations in their genes, cause cancer and other diseases. Here, we review the remarkable …
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis
M Santoni, A Rizzo, J Kucharz, V Mollica… - Cancer Immunology …, 2023 - Springer
Background Immunotherapy has determined unprecedented long-term responses in several
hematological and solid tumors. In the MOUSEION-03 study, we conducted a meta-analysis …
hematological and solid tumors. In the MOUSEION-03 study, we conducted a meta-analysis …
CD8+ T Cell Exhaustion in Cancer
JS Dolina, N Van Braeckel-Budimir… - Frontiers in …, 2021 - frontiersin.org
A paradigm shift in the understanding of the exhausted CD8+ T cell (Tex) lineage is
underway. Originally thought to be a uniform population that progressively loses effector …
underway. Originally thought to be a uniform population that progressively loses effector …
B cell function in the tumor microenvironment
SM Downs-Canner, J Meier, BG Vincent… - Annual review of …, 2022 - annualreviews.org
The tumor microenvironment (TME) is a heterogeneous, complex organization composed of
tumor, stroma, and endothelial cells that is characterized by cross talk between tumor and …
tumor, stroma, and endothelial cells that is characterized by cross talk between tumor and …
Clinical cancer immunotherapy: Current progress and prospects
C Liu, M Yang, D Zhang, M Chen, D Zhu - Frontiers in immunology, 2022 - frontiersin.org
Immune checkpoint therapy via PD-1 antibodies has shown exciting clinical value and
robust therapeutic potential in clinical practice. It can significantly improve progression-free …
robust therapeutic potential in clinical practice. It can significantly improve progression-free …
MAPK/ERK signaling pathway in hepatocellular carcinoma
H Moon, SW Ro - Cancers, 2021 - mdpi.com
Simple Summary The mitogen-activated protein kinase/extracellular signal-regulated kinase
(MAPK/ERK) signaling pathway is frequently activated in liver cancer, which is one of the …
(MAPK/ERK) signaling pathway is frequently activated in liver cancer, which is one of the …
Reprogramming the Tumor Microenvironment through Second‐Near‐Infrared‐Window Photothermal Genome Editing of PD‐L1 Mediated by Supramolecular Gold …
A photothermal genome‐editing strategy is described to improve immune checkpoint
blockade (ICB) therapy by CRISPR/Cas9‐mediated disruption of PD‐L1 and mild …
blockade (ICB) therapy by CRISPR/Cas9‐mediated disruption of PD‐L1 and mild …